20.85
+1.01(+5.09%)
Currency In USD
| Previous Close | 19.84 |
| Open | 19.99 |
| Day High | 21.07 |
| Day Low | 19.7 |
| 52-Week High | 30.03 |
| 52-Week Low | 13.3 |
| Volume | 798,365 |
| Average Volume | 517,943 |
| Market Cap | 1.24B |
| PE | -10.48 |
| EPS | -1.99 |
| Moving Average 50 Days | 20.6 |
| Moving Average 200 Days | 21.15 |
| Change | 1.01 |
If you invested $1000 in Enliven Therapeutics, Inc. (ELVN) since IPO date, it would be worth $347.5 as of August 24, 2025 at a share price of $20.85. Whereas If you bought $1000 worth of Enliven Therapeutics, Inc. (ELVN) shares 3 years ago, it would be worth $4,572.37 as of August 24, 2025 at a share price of $20.85.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Enliven Therapeutics Announces Positive Data Update from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia
GlobeNewswire Inc.
Sep 28, 2024 1:35 PM GMT
Updated Phase 1 data presented at ESH-iCMLf 26th Annual John Goldman Conference Reported cumulative MMR rate of 44% (8/18) by 24 weeks, with stable or deepening responses between weeks 12 and 24, which continues to compare favorably to precedent Phas
Enliven Therapeutics Announces Details Regarding the Presentation of Updated ELVN-001 Phase 1a Data at the ESH-iCMLf 26th Annual John Goldman Conference on CML
GlobeNewswire Inc.
Sep 18, 2024 8:05 PM GMT
BOULDER, Colo., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inh